J&J's Janssen and PATH Partner to Develop Rilpivirine Formulation - - BioPharm International

ADVERTISEMENT

J&J's Janssen and PATH Partner to Develop Rilpivirine Formulation



PATH, an international nonprofit organization, has entered into a licensing agreement with Janssen R&D Ireland to develop an injectable form of the HIV medicine rilpivirine, part of Johnson and Johnson.

The agreement allows PATH and its partners, Janssen, the HIV Prevention Trials Network, and the Division of AIDS at the National Institutes of Health, to advance the product to Phase II multisite safety studies in the US and Africa, with trials expected to begin in 2014. The trials will build on the results of ongoing Phase I work to establish the viability of the drug candidate.

An injectable formulation of rilpivirine could become a new pre-exposure prophylaxis (PrEP) intervention against HIV type 1. PrEP is a prevention strategy that involves the use of antiretroviral medications to reduce the risk of HIV infection in healthy uninfected people at risk for acquiring the virus.

Rilpivirine is a highly potent, non-nucleoside reverse transcriptase inhibitor of HIV-1, currently commercialized by Janssen as an oral, once-daily treatment for adults who have not been treated previously with antiretroviral therapy. It is used in combination with other antiretroviral therapies

Source: PATH

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines

Click here